Featured
Ono Pharmaceutical Enters into Drug Discovery Collaboration Agreement with Twist Bioscience
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced a drug discovery agreement with Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President and CEO: Gyo Sagara; “Ono”) to discover and develop novel antibodies for the treatment of autoimmune diseases.
Mitsui to expand health startup investment with focus on ASEAN
Japanese trading house Mitsui & Co. plans to increase fivefold its investments in medical startups over the next three years, with a focus in Southeast Asian companies.
ENHERTU® Granted Two Breakthrough Therapy Designations in U.S. for Patients Across Multiple HER2 Expressing Cancers
ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been granted two additional Breakthrough Therapy Designations (BTDs) in the U.S. for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors.
Innovac Therapeutics Completes $18 million Series Pre-A Financing To Fund the Development of Its lead Programs and Manufacturing Capabilities
Innovac Therapeutics, an mRNA therapeutics company, today announced the completion of an $18 million Series Pre-A financing
Verastem Oncology Enters Discovery and Development Collaboration with GenFleet Therapeutics to Advance New Programs Targeting RAS Pathway-Driven Cancers
Verastem Oncology (Nasdaq: VSTM) (the “Company”), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that the Company has entered into a discovery and development collaboration with GenFleet Therapeutics (“GenFleet”) to advance three oncology discovery programs targeting RAS pathway-driven cancers.
A China fund from Fidelity is beating the crowd. How it plans to keep doing it
Fidelity’s China Focus Fund is setting up for another year of outperformance, after ranking first last year among China equity funds tracked by Morningstar.
SoftBank-backed Neumora Therapeutics files for U.S. IPO
Neumora Therapeutics, a biopharmaceutical firm backed by biotech Amgen and Japan's SoftBank, on Friday filed for an initial public offering of its shares in New York.
Gina Raimondo hails ‘important beginning’ for US-China ties, wraps up trip at Boeing, Disneyland in Shanghai
US Commerce Secretary Gina Raimondo hailed 'an important beginning' for Beijing and Washington to manage tensions on Wednesday, while also calling on China to address market concerns for American firms.
China says the best way to ‘de-risk’ is to restore stability with the U.S.
China’s Ministry of Commerce said Thursday that restoring stability in U.S.-China trade relations is the best way to 'de-risk' — a twist to a term that’s become popular in international politics.
HUTCHMED Receives Breakthrough Therapy Designation in China for Savolitinib for Gastric Cancer
HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the Center for Drug Evaluation of China’s National Medical Products Administration (“NMPA”) has granted Breakthrough Therapy Designation (“BTD”) to savolitinib.
